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ApoptosisThe mechanisms by which opioids affect progression of human immunodeﬁciency virus type 1 (HIV-1)
infection are not well-deﬁned. HIV-1 gp120 is important in the apoptotic death of uninfected, bystander T
cells. In this study, we show that co-treatment of human peripheral blood mononuclear cells (PBMC) with
HIV-1 gp120/morphine synergistically induces apoptosis in PBMC. Co-treatment of murine splenocytes from
μ opiate receptor knockout mice with gp120/morphine resulted in decreased apoptosis when compared to
splenocytes from wild type mice. Co-treatment of human PBMC or murine splenocytes with gp120/
morphine led to decreased expression of β-arrestin 2, a protein required for opioid-mediated signaling. The
role of β-arrestin 2 was conﬁrmed in Jurkat lymphocytes, in which 1) over-expression of β-arrestin 2
inhibited gp120/morphine-induced apoptosis and 2) RNA interference of β-arrestin 2 expression enhanced
gp120/morphine-induced apoptosis. These data suggest a novel mechanism by which HIV-1 gp120 and
opioids induce lymphocyte cell death.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Infection with human immunodeﬁciency virus type 1 (HIV-1) is
characterized by progressive immunodeﬁciency with loss of CD4+ T
cells [1]. Intravenous opioid drug use is a major risk factor and the
fastest growing means for spread of HIV-1 infection [2]. These drugs
have been proposed as cofactors in the progression of HIV-1 and the
pathogenesis of AIDS [3–6]. Recent studies report that chronic opioid
abuse enhances HIV-1 viral load and dramatically and adversely
affects CD4+ T cell recovery upon treatment of naïve HIV-1-infected
individuals [7,8]. Activation of the μ opioid receptor (μOR) by agonists
enhances expression of CXCR4, CCR3 and CCR5, major cytokine
receptors that serve as HIV-1 co-receptors [9]. Other studies suggest
that morphine enhances HIV-1 growth in human peripheral blood
mononuclear cells (PBMC), a process that can be reversed upon μOR
blockade using the opioid receptor antagonist naloxone [4].
While the loss of T cells leading to clinical deterioration in infected
individuals can be explained by multiple mechanisms, HIV-1-inducedMedicine and Pharmacology,
Johnson City, TN 37614, USA.
ll rights reserved.apoptosis of uninfected, bystander cells has been postulated to be a
major contributor to cell loss [10]. The envelope protein gp120 is one
of the most consistently studied HIV-1 viral proteins shown to be
involved in the apoptotic death of bystander lymphocytes, and this
protein circulates in a soluble form in individuals with HIV-1 infection
[11–13]. Studies in neuronal cells have indicated that morphine
signiﬁcantly enhances gp120- or Tat-induced apoptosis through the
p38 mitogen-activated protein kinase (MAPK) signaling pathway
[3,14]. In addition, gp120 has recently been shown to up-regulate μOR
expression [15]. Howgp120 affects immune responses in the setting of
opiate abuse, however, remains unclear.
Recent studies of opioid signaling have implicated the arrestin
family as major negative regulators of G protein coupled receptor
(GPCR) signaling pathways, serving as scaffolds and adapters to
connect the receptors to cellular trafﬁcking machinery such as the
MAPKs [16,17]. Of the four arrestins described,β-arrestin 2 is expressed
highly in lymphatic and nervous tissues and has been linked to μOR
regulation [18,19]. Mice deﬁcient in β-arrestin 2, for example, exhibit
prolonged and enhanced opioid-mediated analgesia due to impairment
of μOR sensitization, yet display a reduction in opioid tolerance [20].
β-arrestin 2 is the predominant arrestin expressed in T and B
lymphocytes [21], but its importance to in vivo immune responses has
yet to be elucidated. The protein can regulate chemotactic responses and
granule release as a function of its scaffold and adapter functions [21,22],
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absence of β-arrestin 2, stimulation of various GPCRs induces apoptosis.
In reference to HIV-1 infection, the role of gp120 in altering
lymphocyte apoptotic signaling in the setting of opioid exposure has
not been investigated. In addition, if and how β-arrestin 2 is involved
in this process as an anti-apoptotic regulator is unclear. In this study,
we attempt to clarify the effect and mechanism of opioid co-factor
signaling on gp120-mediated lymphocyte apoptosis. To this end, we
analyzed the apoptotic responses of PBMC and lymphocyte cell lines
co-treated with gp120 and morphine in an in vitro model of HIV-1-
induced cell death. We show HIV-1 gp120 primes lymphocytes for
morphine-mediated apoptosis. We also describe the synergistic
reduction in β-arrestin 2 expression in lymphocytes co-treated with
gp120 andmorphine. We report that β-arrestin 2 over-expression and
interference can decrease and increase, respectively, the level of
gp120/morphine-induced lymphocyte apoptosis. These ﬁndings
suggest a novel role for opiates in HIV-1-mediated lymphocyte
apoptosis mediated via β-arrestin 2 signaling.
2. Materials and methods
2.1. Materials
Morphine was obtained from Sigma (St. Louis, MO). Human Jurkat
leukemia cell line was purchased from the American Type Culture
Collection (Manassas, VA). Peripheral blood mononuclear cells
(PBMC) were isolated from healthy subjects by Ficoll density
centrifugation with lympholyte-H (Cedarlane Labs, Ontario, Canada)
and then cryopreserved in freezing medium (10% DMSO, 20% FBS in
RPMI 1640) in liquid nitrogen until examined. Human Jurkat cells
were cultured in RPMI 1640 medium (GIBCO) supplemented with
sodium pyruvate, L-glutamate, 5% heat-inactivated Fetal bovine serum
(FBS) (Sigma, St. Louis, MO), 100 U/ml penicillin and 100 μg/ml
streptomycin. Cultures were incubated at 37 °C and 5% CO2 in a fully
humidiﬁed incubator. They were passed twice weekly, and prepared
for experimental procedures when in log-phase growth. μOR KO mice
were a generous gift of Dr. Srinivasa Raja, Johns Hopkins University
School of Medicine, Baltimore, MD [24]. β-arrestin 2 KO mice were a
generous gift from Dr. Robert Lefkowitz, Duke University Medical
Center, Durham, NC.
2.2. Transient transfection of Jurkat cells
For transfections, cells (2×107) in 0.5 ml of Opti-MEMwere mixed
with 10 μg of each DNA construct by electroporation using a Gene
Pulser Electroporator (Bio-Rad) set at 250 V, 960AF as described [25].
After electroporation, the cells were kept on ice for 15 min and
resuspended in 15 ml of complete RPMI 1640 medium, and incubated
at 37 °C in 5% FBS. Sixteen hours after transfection some of the cells
were lysed for Western blot analysis as described below. The other
cells were further incubated for 36 h in either morphine at 3 μM for
lymphocytes or at 10 μM for Jurkat leukemia cells [25] for apoptotic
assay as described below.
2.3. Apoptosis assay
Apoptotic cells were examined by ﬂow cytometry as described in
our previous publications [26]. Brieﬂy, cells were harvested by
centrifugation at 400 ×g for 5 min and ﬁxed in 1 ml 70% ethanol at
4 °C overnight, then washed twice with PBS. After centrifugation, the
cells were resuspended in 0.5 ml of staining solution (50 μg/ml of
propidium iodide and 10 μg/ml RNase in TBS) followed by incubation
at room temperature for 30 min. DNA content was analyzed by ﬂow
cytometry using a FACScanmicroﬂuorometer (Becton-Dickinson). The
percentage of apoptotic cells was calculated from ﬂow cytometric
analysis. All of the experiments were conducted at least three times.2.4. Isolation of RNA
Total RNA was isolated from spleens using the VERSAGENE™ RNA
Tissue Kit (Gentra SYSTEMS; Minnesota) according to the manufac-
turer's instructions. DNAse I treatment (Qiagen, Chatsworth, CA) was
applied to eliminate genomic DNA interference [25]. RNA quality was
determined by running a sample with a RNA loading dye (Sigma-
Aldrich) on a 1% agarose gel and inspecting for distinct 18 S and 28 S
bands, indicating lack of degradation. Quantity was determined by
A260 measurement. Samples were frozen at −80 °C until use.
2.5. Real-time quantitative reverse transcription polymerase chain
reaction (RT-PCR)
The real-time PCR detection techniquewas performed as described
recently. Brieﬂy, ﬁrst-strand cDNA was synthesized from 1 μg of total
RNA in a ﬁnal volume of 50 μl using a Reaction Ready™ ﬁrst-strand
cDNA synthesis kit (SuperArray Bioscience Corporation, Frederick,
MD). After incubation at 70 °C for 3 min and cooling down to 37 °C for
10 min, RT cocktail was added to the annealing mixture and further
incubated at 37 °C for 60min. Twomicroliters of 1:2 diluted cDNAwas
subjected to real-time quantitative PCR using Bio-Rad iCycler iQ
Multicolor Real-Time PCR Detection System (Bio-Rad Life Science
Research, Hercules, CA). PCRwas performed in a 50 μl volume using RT
2 real-time ™ SYBR Green Fluorescien PCR Master Mix (SuperArray
Bioscience Corporation). All primers were purchased from SuperArray
Bioscience Corporation. All PCR assays were performed in triplicate.
The reaction conditionswere: 95 °C for 12min; followed by40 cycles at
95 °C for 15 s, 55 °C for 30 s, and 72 °C for 30 s. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and β-Actin were ampliﬁed from
all samples on each plate as housekeeping genes to normalize expres-
sion levels of targets between different samples, and to monitor assay
reproducibility. The reaction mixtures without template cDNA were
used as negative controls. Threshold cycle numbers (CT) were
determined with Bio-Rad iCycler iQ Multicolor Real-Time PCR
Detection System (version 1.1 software) and transformed using the
ΔCT comparative method. Gene-speciﬁc expression values were nor-
malized to expression values of GAPDH and/or β-actin (endogenous
control) within each sample. Relative quantiﬁcation was performed
using the comparativemethod. The amount of target, normalized to an
endogenous reference and relative to a calibrator, was determined by
the comparative Ct method (ΔΔCT). In brief, the ΔCT value was deter-
minedby subtracting the averageGAPDHCTand/orβ-Actin value from
the average target gene value in the same sample. The calculation of
ΔΔCT involves subtraction of the ΔCT calibrator value.
2.6. Statistical analysis
The results were presented as mean±S.D. The data were analyzed
using one-way analysis of variance (ANOVA) followed by Bonferroni
tests to determinewhere differences among groups existed. Statistical
signiﬁcance was accepted when pb0.05.
3. Results
3.1. gp120 primes human peripheral blood mononuclear cells to
morphine-mediated apoptosis
Opioids have been proposed as cofactors in the progression of HIV-
1 infection and pathogenesis of AIDS [6]. Although it has been reported
recently that morphine sensitizes neuronal cells to gp120-induced
apoptosis [3], the molecular mechanisms by which opioids and HIV-1
inﬂuence immune cell function remain to be elucidated.We examined
whether gp120 synergizes with morphine in inducing apoptosis in
human peripheral blood mononuclear cells (PBMC). Freshly isolated
PBMC were treated with gp120 and cross-linked with anti-gp120
Fig. 1. Effect of gp120/anti-gp120 and morphine on lymphocyte apoptosis. gp120/anti-
gp120 and morphine induces apoptosis in human PBMC. PBMC were incubated with
gp120 (150 ng/ml) for 1 h at 4 °C, followed by addition of polyclonal anti-gp120
(150 ng/ml) as described. After 1 h incubation at 37 °C, morphine sulfate (3 μM) was
added. After 24 h, cell apoptosis was assayed by ﬂow cytometry after staining with
propidium iodide. ⁎pb0.01 vs control, morphine, and gp120/anti-gp120. ⁎⁎pb0.01 vs
morphine and gp120/anti-gp120.
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or absence ofmorphine.We have reported thatwithmorphine at 3 μM,
it worked well for lymphocytes, so that we still used this dosage in
treatment of lymphocytes, including human PBMC and murine
splenocytes. As shown in Fig. 1, signiﬁcantly greater PBMC apoptosis
was observed when PBMC cells were exposed to both gp120/anti-
gp120 and morphine than when they were exposed to gp120/anti-
gp120 or morphine alone. Anti-gp120 alone or gp120 alone did not
induce cell apoptosis (data not shown). Similar results were observed
in human Jurkat T cells (data not shown). This synergistic effect was
signiﬁcantly blocked by treatment of the PBMC with the opioid
receptor antagonist naloxone, suggesting that this synergistic effect
requires opioid receptors (data not shown).
3.2. gp120/anti-gp120 and morphine-induced splenocyte apoptosis
through μ opioid receptor
It has been recently reported that gp120 up-regulates the μ opioid
receptor (μOR) in immune cells [15]. We therefore questioned
whether μOR is involved in this synergistic effect of gp120 andFig. 2. gp120/anti-gp120 and morphine-induced apoptosis in splenocytes occurs
through the μ opioid receptor. Splenocytes fromwild type and μOR knockout mice were
treated with gp120/anti-gp120 andmorphine as above. Splenocytes were collected and
cell apoptosis determined as above. ⁎pb0.01 vs a combination of gp120/anti-gp120 and
morphine in splenocytes from wild type mice.morphine. Splenocytes from wild type mice and μOR knockout mice
were treated with gp120 and cross-linked with anti-gp120 antibody,
with or without morphine treatment. Neither gp120/anti-gp120 nor
morphine alone had a signiﬁcant effect on the induction of apoptosis
in splenocytes (data not shown). As shown in Fig. 2, the apoptosis
induced by gp120/morphine was signiﬁcantly decreased in the
splenocytes from μOR knockout mice compared to the splenocytes
fromwild typemice, strongly indicating that μOR plays a crucial role in
gp120/anti-gp120 and morphine-induced apoptosis in lymphocytes.
3.3. gp120/anti-gp120 and morphine-induced apoptosis is mediated
by β-arrestin 2
β-arrestin 2 is an essential protein required for opioid-mediated
signaling in the nervous system [17,29]. Although it is established that
β-arrestin 2 is abundantly expressed on lymphocytes [21], the
molecular mechanisms by which β-arrestin 2 inﬂuence immune cell
function remain largely unclear. To investigate the role of β-arrestin 2
in the immune system, we treated human PBMC cells and human
Jurkat cells with morphine and/or gp120/anti-gp120 and assayed theFig. 3. gp120/morphine-mediated apoptosis is mediated by β-arrestin 2 expression (a).
gp120/morphine reduces β-arrestin 2 expression. Freshly isolated human PBMC were
treated with gp120 (150 ng/ml) for 1 h at 4 °C, followed by addition of polyclonal anti-
gp120 (150 ng/ml). After 1 h at 37 °C, PBMC were treated with 3 μM morphine sulfate
for 2 h and the expression of β-arrestin 2 was determined by real-time quantitative RT-
PCR. ⁎pb0.01 vs control, morphine, and gp120/anti-gp120. (b). gp120/morphine-
induced apoptosis is inhibited by over-expression of β-arrestin 2. Jurkat T cells
transfectedwith pcDNA3-GFP or pcDNA3/β-arrestin 2 were incubated for 16 h and then
treated with gp120 (150 ng/ml) for 1 h at 4 °C, followed by the addition of polyclonal
anti-gp120 (150 ng/ml). After 1 h at 37 °C, cells were treated with 10 μM morphine
sulfate for an additional 36 h and the percent apoptosis was determined by ﬂow
cytometric analysis. Mean values were derived from three independent experiments.
⁎pb0.01 compared to transfected pcDNA3-GFP.
Fig. 5. gp120/morphine-induced apoptosis in splenocytes requires β-arrestin 2. Sple-
nocytes fromwild type mice and β-arrestin 2 knockout mice were treated with gp120/
anti-gp120 and morphine as in a. Cell apoptosis was determined as in a. ⁎pb0.01 vs. a
combination of gp120/anti-gp120 and morphine in splenocytes fromwild type mice.
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transcription polymerase chain reaction (RT-PCR). Co-treatment of
human PBMC with gp120/anti-gp120 and morphine signiﬁcantly
enhanced the reduction of gene expression of β-arrestin 2 compared
with gp120/anti-gp120 or morphine treatment alone (Fig. 3a). Anti-
gp120 alone or gp120 alone did not alter the expression level of β-
arrestin 2 (data not shown). Similar results were observed in human
Jurkat cells (data not shown).
Sincegp120/anti-gp120enhances thenegative effectofmorphineon
the expression of β-arrestin 2 (Fig. 3a), and β-arrestin 2 plays a critical
role inpreventing apoptosis [17,23],wequestionedwhetherβ-arrestin 2
could play a role in the synergistic effect of gp120/morphine on
lymphocyte apoptosis. As shown in Fig. 3b, over-expression ofβ-arrestin
2 via transfection of β-arrestin 2 plasmid [22] signiﬁcantly inhibits the
synergistic effect on gp120/anti-gp120 and morphine-induced human
Jurkat Tcell apoptosis. Neither gp120alonenoranti-gp120alonehadany
effect on the induction of apoptosis (data not shown).
3.4. Suppression of β-arrestin 2 by RNAi increases gp120/anti-gp120 and
morphine-induced apoptosis
We next used β-arrestin 2 RNAi to characterize the role of
endogenous β-arrestin 2 on the synergistic effect of gp120/anti-Fig. 4. Inhibition of β-arrestin 2 expression by RNAi enhances gp120/morphine-
induced apoptosis. (a). Suppression of endogenously-expressed β-arrestin 2 using RNA
interference. Jurkat T cells were transfected with 50 nM control RNAi or 50 nM β-
arrestin 2 RNAi for 24 h. The expression of β-arrestin 2 was determined by real-time
quantitative PCR. (b). Apoptotic response of lymphocytes to gp120/anti-gp120 and
morphine following β-arrestin 2 RNA interference. Jurkat T cells were transfected with
GFP orβ-arrestin 2 RNAi plasmids or control vector, cells treatedwith gp120/anti-gp120
and morphine, and analysis of apoptosis performed as described above. ⁎pb0.01
compared with transfected control RNAi.gp120 and morphine in inducing apoptosis. We ﬁrst transfected
human Jurkat T cells with RNAi plasmid of β-arrestin 2 or the control
RNAi plasmid [22], and found that the expression of endogenous β-
arrestin 2 was remarkably reduced compared to the control level as
detected by real-time quantitative RT-PCR (Fig. 4a), while the
expression of GAPDH as a control was not affected under the same
conditions. Further experiments showed that a signiﬁcant increase in
apoptosis was observed following co-treatment with gp120/anti-
gp120 and morphine when the expression of β-arrestin 2 was
knocked down by β-arrestin 2 RNAi (Fig. 4b).
3.5. gp120/anti-gp120 and morphine-induced splenocyte apoptosis
requires β-arrestin 2
To further test the effect of β-arrestin 2 on gp120/anti-gp120 and
morphine-induced apoptosis, splenocytes from β-arrestin 2 knockout
mice andwild typemice were incubated with gp120/anti-gp120 and/
or morphine. Neither gp120/anti-gp120 nor morphine alone had a
signiﬁcant effect on the induction of apoptosis in splenocytes (data
not shown). As shown in Fig. 5, gp120/anti-gp120 and morphine-
induced apoptosis was signiﬁcantly increased in the splenocytes from
β-arrestin 2 knockout mice compared to the splenocytes from wild
type mice. These results indicate that β-arrestin 2 is a potential
inhibitor of the synergistic effect on gp120/morphine on lymphocyte
apoptosis.
4. Discussion
It is clear that HIV-1 exploits the host's cellular apoptotic machi-
nery, inducing premature lymphocyte apoptosis in lymphoid organs
and affecting all lymphocyte subsets, including CD4+ and CD8+ T
cells, B cells, and dendritic cells. This premature death occurs in
uninfected, bystander cells and is independent of the cytopathic effect
of HIV-1 [1]. Death of bystander cells by secreted, pro-apoptotic viral
proteins such as gp120 is a major mechanism by which apoptosis and
progressive lymphocyte depletion occurs. gp120 has been shown to
bind to and cross-link with the CD4 receptor [28], and stimulates pro-
apoptotic signals through an action on chemokine receptors CXCR4
and CCR5 [8,11,30]. HIV-1-driven lymphocyte apoptosis remains
perhaps the most important factor in immune destruction during
HIV-1 infection.
Based in part on the ability of opioids to modulate HIV-1
propagation in the immune system [5,31], opioids have been proposed
as cofactors in the progression of HIV-1 infection and pathogenesis of
AIDS [3,6]. Recent studies report that chronic opioid abuse enhances
viral load [7] and dramatically worsens CD4+ cell recovery in naive
HIV-1-infected patients [8], indicating that the progression of HIV-1 is
signiﬁcantly affected by opioids. In this study, we employed amodel in
which gp120 cross-linked with anti-gp120 antibody induced
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mimics the in vivo situation of HIV-1 infection, in which gp120 is shed
from infected cells and is found on the surface of infected cells and free
virus. Investigators have used additional anti-CD3 antibody to activate
TCR in this model [13], but our data show that PBMCs co-treated with
gp120/morphine exhibit higher levels of cell death even in the
absence of TCR stimulation when compared to gp120 or morphine
alone. Our data also conﬁrm several key studies that suggest a role for
gp120 in priming lymphocytes for cell death [28].
The apoptosis we observed upon co-treatment is clearly depen-
dent upon μ opioid receptor (μOR) signaling, as demonstrated in our
μOR knockout mouse model. Splenocytes from wild type mice that
were co-treated with gp120/anti-gp120 and morphine behaved quite
similarly to human PBMCs in terms of apoptosis, while splenocytes
from μOR knockoutmice exhibited decreased levels of apoptosis. Hu et
al. also found a synergistic apoptotic effect of gp120/morphine while
studying neuronal cells and this was naloxone-dependent, supporting
the involvement of an opiate receptor [3]. While our study reveals a
role for μOR, its exact function during this process remains unclear.
Recently, Beltran et al. found that gp120 can up-regulate μOR
expression in TPA-differentiated HL-60 cells at the transcriptional
level, ﬁndings that suggest one potential mechanism by which gp120
primes lymphocytes [32]. Thus, while morphine treatment of
lymphocytes alone is not able to induce signiﬁcant apoptosis, μOR
up-regulation may occur on lymphocytes in response to gp120, and
subsequent apoptosis may be triggered in response to relatively
greater morphine-mediated signaling. Further analysis of μOR
expression in lymphocytes in response to gp120 is warranted.
Studies indicate that opioid receptors can modify HIV-1 progres-
sion [33]. Morphine promotes the growth of HIV-1 in human PBMCs, a
process that is dependent on functional opioid receptors since
morphine-induced HIV-1 growth could be reversed by naloxone [4].
Activation of μOR by μOR agonists also enhances the expression of
cytokine receptors that serve as co-receptors for HIV-1, including
CXCR4, CCR3, and CCR5 [9,33]. As noted above, gp120 has been shown
to stimulate its apoptotic activity via these chemokine receptors
[8,11,30].
Because of the involvement of β-arrestin in regulating not only μOR
(a G protein coupled receptor, GPCR) function but also apoptotic
signaling pathways, our studies focused on the expression of this key
adaptor during co-treatment of lymphocytes with gp120/morphine.
Our in vitro studies in human PBMCs conﬁrmed a synergistic decrease
in β-arrestin expression by real-time RT-PCR. Consistent with our
ﬁndings, β-arrestin 2 was found to be anti-apoptotic in several key
studies. Revankar et al. have shown that arrestins play a critical role in
suppressing the apoptosis mediated by stimulated GPCRs using β-
arrestin 1/2 knockout cells [23], and DeFea et al. found that substance
P inhibits apoptosis via β-arrestin signaling [34]. Povsic et al.
demonstrated that an IGF1-mediated anti-apoptotic effect was lost
in β-arrestin 1/2 knockout MEFs, but could be restored with
transfection of β-arrestin 1 [35].
Similar to the approach in these studies, we were also able to
inhibit gp120/morphine-mediated lymphocyte apoptosis by over-
expression of β-arrestin 2 in Jurkat cells. Using RNA interference to
inhibit endogenous β-arrestin 2 expression, we found enhanced
apoptosis of lymphocytes in response to co-treatment. Finally, using a
β-arrestin 2 knockout mouse model, we conﬁrmed this enhanced
apoptotic response upon co-treatment of murine splenocytes. These
data strongly support an anti-apoptotic function for β-arrestin 2 in
gp120-primed lymphocytes treated with morphine.
Because the β-arrestins function as fundamental adaptors con-
necting receptors to cell trafﬁcking machinery [29], there are multiple
potential pathways by which β-arrestin 2 might be protecting
lymphocytes from apoptotic death. Recently, β-arrestins have been
shown to regulate GPCR localization and internalization as well as
GPRC-mediated activation of MAPKs, including the ERK1/2 and JNK3signaling pathways that have been linked to cell survival
[29,34,36,37]. β-arrestin 2 can also inhibit NF-κB [38], which plays a
central role in regulating expression of genes responsible for both
apoptosis and cell proliferation. How β-arrestin 2 alters these
signaling cascades during gp120/morphine-mediated lymphocyte
apoptosis is as yet unknown but is under investigation.
Another potential mediator in gp120/morphine-mediated apop-
tosis is the Fas/FasL signaling cascade, although the relationship
between Fas/FasL and β-arrestin signaling remains unknown. Nota-
bly, gp120 has been shown to prime T cells for Fas-mediated,
activation-induced apoptosis by up-regulation of FasL and Fas
expression, a mechanism that has been suggested as one that might
lead to T cell depletion during HIV-1 infection [30]. Recent studies by
Anand et al. suggested that CD45 regulates gp120-mediated apoptosis
in Jurkat clones by up-regulating FasL expression [13]. Interestingly,
and consistent with the previous studies by Westendorp et al. [24],
blocking FasL binding only partially inhibited apoptosis, suggesting
this is not the only pathway involved. We have previously shown that
morphine treatment of PBMCs leads to up-regulation of Fas expres-
sion and sensitization to Fas-mediated apoptotic cell death [39]. It is
feasible that exposure to both gp120 and morphine might lead to
synergistic increases in Fas and/or FasL expression above a threshold
to induce apoptosis.
Taken together, our data suggest an important role for β-arrestin 2
during gp120/morphine-mediated apoptosis. Speciﬁcally, our results
demonstrate that gp120/morphine co-treatment induces lymphocyte
apoptosis by a novel mechanism that involves down-regulation of β-
arrestin 2. These data shed new light on the progressive lymphocyte
depletion observed during HIV infection in the setting of drug abuse
and may provide a new target for anti-apoptotic therapy of bystander
T cells.
Acknowledgments
This work was supported by the National Institutes of Health (NIH)
grant DA020120 and the East Tennessee State University Research
Development Committee (ETSU RDC) grants 2-25491 to D. Yin and
06-002M to J. Moorman. The authors wish to express their apprecia-
tion to Dr. Srinivasa Raja, Johns Hopkins University School of Medicine,
for providing μOR knockout mice and to Dr. Robert Lefkowitz, Duke
University Medical School, for providing β-arrestin knockout mice.
References
[1] M.L. Gougeon, To kill or be killed: how HIV exhausts the immune system, Cell
Death Differ. Suppl. 1 (2005) 845–854.
[2] H. Francis, Substance abuse and HIV infection, Top. HIV Med. 11 (2003) 20–24.
[3] S. Hu, W.S. Sheng, J.R. Lokensgard, P.K. Peterson, Morphine potentiates HIV-1
gp120-induced neuronal apoptosis, J. Infect. Dis. 191 (2005) 886–889.
[4] P.K. Peterson, B.M. Sharp, G. Gekker, P.S. Portoghese, K. Sannerud, H.H. Balfour,
Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear
cell cocultures, AIDS 4 (1990) 869–873.
[5] B.M. Sharp, G. Gekker, M.D. Li, C.C. Chao, P.K. Peterson, Delta-opioid suppression of
human immunodeﬁciency virus-1 expression in T cells (Jurkat), Biochem.
Pharmacol. 56 (1998) 289–292.
[6] R.M. Donahoe, D. Vlahov, Opiates as potential cofactors in progression of HIV-1
infections to AIDS, J. Neuroimmunol. 83 (1998) 77–87.
[7] R. Kumar, C. Torres, Y. Yamamura, I. Rodriguez, M. Martinez, S. Staprans, R.M.
Donahoe, E. Kraiselburd, E.B. Stephens, A. Kumar, Modulation bymorphine of viral
set point in rhesus macaques infected with simian immunodeﬁciency virus and
simian-human immunodeﬁciency virus, J. Virol. 78 (2004) 11425–11428.
[8] F. Dronda, J. Zamora, S. Moreno, A. Moreno, J.L. Casado, A. Muriel, M.J. Perez-Elias,
A. Antela, L. Moreno, C. Quereda, CD4 cell recovery during successful antiretroviral
therapy in naive HIV-infected patients: the role of intravenous drug use, AIDS 18
(2004) 2210–2212.
[9] A.D. Steele, E.E. Henderson, T.J. Rogers, Mu-opioid modulation of HIV-1 coreceptor
expression and HIV-1 replication, Virology 309 (2003) 99–107.
[10] G. Pantaleo, A.S. Fauci, Apoptosis in HIV infection, Nat. Med. 1 (1995) 118–120.
[11] C. Cicala, J. Arthos, A. Rubbert, S. Selig, K. Wildt, O.J. Cohen, A.S. Fauci, HIV-1
envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in
primary human CD4(+) T cells, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1178–1183.
[12] R. Roggero, V. Robert-Hebmann, S. Harrington, J. Roland, L. Vergne, S. Jaleco, C.
Devaux, M. Biard-Piechaczyk, Binding of human immunodeﬁciency virus type 1
1371J. Moorman et al. / Biochimica et Biophysica Acta 1793 (2009) 1366–1371gp120 to CXCR4 induces mitochondrial transmembrane depolarization and
cytochrome c-mediated apoptosis independently of Fas signaling, J. Virol. 75
(2001) 7637–7650.
[13] A.R. Anand, R.K. Ganju, HIV-1 gp120-mediated apoptosis of T cells is regulated
by the membrane tyrosine phosphatase CD45, J. Biol. Chem. 281 (2006)
12289–12299.
[14] J.A. Gurwell, A. Nath, Q. Sun, J. Zhang, K.M. Martin, Y. Chen, K.F. Hauser, Synergistic
neurotoxicity of opioids and human immunodeﬁciency virus-1 Tat protein in
striatal neurons in vitro, Neuroscience 102 (2001) 555–563.
[15] J.A. Beltran, A. Pallur, S.L. Chang, HIV-1 gp120 up-regulation of themu opioid recep-
tor in TPA-differentiated HL-60 cells, Int. Immunopharmacol. 6 (2006) 1459–1467.
[16] R.J. Lefkowitz, K. Rajagopal, E.J. Whalen, New roles for beta-arrestins in cell
signaling: not just for seven-transmembrane receptors, Mol. Cell 24 (2006)
643–652.
[17] R.J. Lefkowitz, S.K. Shenoy, Transduction of receptor signals by beta-arrestins,
Science 308 (2005) 512–517.
[18] A. Kovoor, V. Nappey, B.L. Kieffer, C. Chavkin, Mu and delta opioid receptors are
differentially desensitized by the coexpression of beta-adrenergic receptor kinase
2 and beta-arrestin 2 in Xenopus oocytes, J. Biol. Chem. 272 (1997) 27605–27611.
[19] H. Haberstock-Debic, K.A. Kim, Y.J. Yu, M. von Zastrow, Morphine promotes
rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons,
J. Neurosci. 25 (2005) 7847–7857.
[20] L.M. Bohn, R.R. Gainetdinov, F.T. Lin, R.J. Lefkowitz, M.G. Caron, Mu-opioid receptor
desensitization by beta-arrestin-2 determines morphine tolerance but not
dependence, Nature 408 (2000) 720–723.
[21] A.M. Fong, R.T. Premont, R.M. Richardson, Y.R. Yu, R.J. Lefkowitz, D.D. Patel,
Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deﬁcient mice,
Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7478–7483.
[22] Y. Sun, Z. Cheng, L. Ma, G. Pei, Beta-arrestin2 is critically involved in CXCR4-
mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK
activation, J. Biol. Chem. 277 (2002) 49212–49219.
[23] C.M. Revankar, C.M. Vines, D.F. Cimino, E.R. Prossnitz, Arrestins block G protein-
coupled receptor-mediated apoptosis, J. Biol. Chem. 279 (2004) 24578–24584.
[24] Y. Guan, J. Borzan, R.A. Meyer, S.N. Raja, Windup in dorsal horn neurons is
modulated by endogenous spinal mu-opioid mechanisms, J. Neurosci. 26 (2006)
4298–4307.
[25] D. Yin, M. Woodruff, Y. Zhang, S. Whaley, J. Miao, K. Ferslew, J. Zhao, C. Stuart,
Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and
anti-apoptotic PI3K/Akt/NF-kappaB pathways, J. Neuroimmunol. 174 (2006)
101–107.[26] D. Yin, L. Zhang, R. Wang, L. Radvanyi, C. Haudenschild, Q. Fang, M.R. Kehry, Y. Shi,
Ligation of CD28 in vivo induces CD40 ligand expression and promotes B cell
survival, J. Immunol. 163 (1999) 4328–4334.
[27] M.O. Westendorp, R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K.M.
Debatin, P.H. Krammer, Sensitization of T cells to CD95-mediated apoptosis by
HIV-1 Tat and gp120, Nature 375 (1995) 497–500.
[28] N.K. Banda, J. Bernier, D.K. Kurahara, R. Kurrle, N. Haigwood, R.P. Sekaly, T.H. Finkel,
Crosslinking CD4 by human immunodeﬁciency virus gp120 primes T cells for
activation-induced apoptosis, J. Exp. Med. 176 (1992) 1099–1106.
[29] L. Ma, G. Pei, Beta-arrestin signaling and regulation of transcription, J. Cell Sci. 120
(2007) 213–218.
[30] M. Biard-Piechaczyk, V. Robert-Hebmann, V. Richard, J. Roland, R.A. Hipskind, C.
Devaux, Caspase-dependent apoptosis of cells expressing the chemokine receptor
CXCR4 is induced by cell membrane-associated human immunodeﬁciency virus
type 1 envelope glycoprotein (gp120), Virology 268 (2000) 329–344.
[31] L. McCarthy, M. Wetzel, J.K. Sliker, T.K. Eisenstein, T.J. Rogers, Opioids, opioid
receptors, and the immune response, Drug Alcohol Depend. 62 (2001) 111–123.
[32] J.A. Beltran, J. Peek, S.L. Chang, Expression and regulation of the mu opioid
peptide receptor in TPA-differentiated HL-60 promyelocytic leukemia cells, Int.
Immunopharmacol. 6 (2006) 1331–1340.
[33] T.J. Rogers, P.K. Peterson, Opioid G protein-coupled receptors: signals at the
crossroads of inﬂammation, Trends Immunol. 24 (2003) 116–121.
[34] K.A. DeFea, Z.D. Vaughn, E.M. O'Bryan, D. Nishijima, O. Dery, N.W. Bunnett, The
proliferative and antiapoptotic effects of substance P are facilitated by formation
of a beta-arrestin-dependent scaffolding complex, Proc. Natl. Acad. Sci. U. S. A. 97
(2000) 11086–11091.
[35] T.J. Povsic, T.A. Kohout, R.J. Lefkowitz, Beta-arrestin1 mediates insulin-like growth
factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-
apoptosis, J. Biol. Chem. 278 (2003) 51334–51339.
[36] P.H. McDonald, C.W. Chow, W.E. Miller, S.A. Laporte, M.E. Field, F.T. Lin, R.J. Davis,
R.J. Lefkowitz, Beta-arrestin 2: a receptor-regulated MAPK scaffold for the
activation of JNK3, Science 290 (2000) 1574–1577.
[37] Y. Li, X. Sun, Y. Zhang, J. Huang, G. Hanley, K.E. Ferslew, Y. Peng, D. Yin, Morphine
promotes apoptosis via TLR2, and this is negatively regulated by beta-arrestin 2,
Biochem. Biophys. Res. Commun. 378 (2009) 857–861.
[38] D.S. Witherow, T.R. Garrison, W.E. Miller, R.J. Lefkowitz, Beta-arrestin inhibits
NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor
IkappaB alpha, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8603–8607.
[39] D. Yin, R.A. Mufson, R. Wang, Y. Shi, Fas-mediated cell death promoted by opioids,
Nature 397 (1999) 218.
